Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSP1601 tablets in nonalcoholic steatohepatitis (NASH) phase IIb trial
CTR20223378Phase 2Active
- Sponsor
- Zhongsheng Pharma
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zsp1601 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Zhongsheng Pharma. Started Jun 2023; status: active.
02
Drugs
zsp1601
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20223378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223378.